{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:10:07Z","timestamp":1759050607358,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Euroimmun"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jneuroim.2020.577260","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T03:52:17Z","timestamp":1588823537000},"page":"577260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Diagnostic features of initial demyelinating events associated with serum MOG-IgG"],"prefix":"10.1016","volume":"344","author":[{"given":"Riccardo","family":"Orlandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gobbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Rosa","family":"Mancinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Zuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Zoccarato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Camera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Donata","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Gajofatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"October","key":"10.1016\/j.jneuroim.2020.577260_bb0005","first-page":"0","article-title":"Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein","volume":"130","author":"Akaishi","year":"2019","journal-title":"Neurochem. Int."},{"issue":"9","key":"10.1016\/j.jneuroim.2020.577260_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J. Neurol."},{"issue":"21","key":"10.1016\/j.jneuroim.2020.577260_bb0015","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577260_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"issue":"Apr","key":"10.1016\/j.jneuroim.2020.577260_bb0025","first-page":"1","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"dos Passos","year":"2018","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577260_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"issue":"December 2019","key":"10.1016\/j.jneuroim.2020.577260_bb0035","doi-asserted-by":"crossref","first-page":"102011","DOI":"10.1016\/j.msard.2020.102011","article-title":"Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: two paradigmatic cases and a review of the literature","volume":"41","author":"Foiadelli","year":"2020","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"10","key":"10.1016\/j.jneuroim.2020.577260_bb0040","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2020.577260_bb0045","first-page":"1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jneuroim.2020.577260_bb0050","first-page":"1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jneuroim.2020.577260_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.jneuroim.2020.577260_bb0060","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577260_bb0065","first-page":"1","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurology"},{"year":"2014","series-title":"Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions Defining the Clinical Course of Multiple Sclerosis. The 2013 Revisions","author":"Lublin","key":"10.1016\/j.jneuroim.2020.577260_bb0070"},{"key":"10.1016\/j.jneuroim.2020.577260_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.jneuroim.2020.577260_bb0080","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577260_bb0085","first-page":"1","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","author":"de Mol","year":"2019","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.jneuroim.2020.577260_bb0090","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2020.577260_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577260_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577260_bb0105","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jneuroim.2020.577260_bb0110","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577260_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2020.577260_bb0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2020.577260_bb0125","doi-asserted-by":"crossref","first-page":"E1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jneuroim.2020.577260_bb0130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/jamaneurol.2018.1055","article-title":"Anti\u2013myelin oligodendrocyte glycoprotein antibody\u2013associated central nervous system demyelination\u2014a novel disease entity?","volume":"75","author":"Weber","year":"2018","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2020.577260_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820302228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820302228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:36:54Z","timestamp":1759048614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820302228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":27,"alternative-id":["S0165572820302228"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577260","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic features of initial demyelinating events associated with serum MOG-IgG","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577260"}}